What is the target price of NVO?

The target price for Novo Nordisk (NVO) varies across analysts, with an average target price of $78.33 indicating a potential upside of 45.22% from the current price. However, a recent development shows a more conservative outlook with BMO Capital lowering its price target to $55.00 from $64.00 while maintaining a Market Perform rating. This shift reflects intensified competitive pressure and a reassessment of Novo Nordisk’s market positioning, particularly with its incretin drugs facing challenges from alternatives like tirzepatide by Eli Lilly.